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ABSTRACT  
Background: In this study, we investigated if a combination of the nutraceutical supplement, EvenFlo and 
folic acid will be superior to the standard stand-alone use of folic acid. 
Methods: We conducted a randomized  double-blind, active-controlled, clinical trial. A total of 70 subjects with 
SCD ages 5-12 years were enrolled into the study with 35 in the intervention group and 35 in the control group; 
61 completed the trial (32 from the intervention group and 29 from the control group).  
Results: Par ticipants in the intervention group were significantly less likely to exper ience cr ises compared 
to subjects in the control group. None of the subjects in the intervention group experienced any form of vaso-
occlusive crisis (VOC) compared to 93.1% of the subjects in the controlled group. Additionally, the intervention 
group experienced a significantly higher increase in their hemoglobin concentration from baseline (2.92 g/dL, 
95% CI [2.33, 3.51]) compared the control group (1.77 g/dL, 95% CI [1.00, 2.54]). The intervention group experi-
enced a significantly higher increase in their mean weight from baseline (4.47 Kg, 95% CI [4.02, 4.92]) while the 
control group experienced a decrease (-1.05 Kg, 95% CI [-1.60, -0.51]). 
Conclusions: EvenFlo is a nutr itional supplement effective in the management of SCD when combined with 
folic acid; its beneficial effect would be useful in boosting the hemoglobin concentration and weight indices indi-
viduals with SCD as well as and in limiting the crises they suffered. 
Keywords: sickle cell anemia, sickle cell disease, SCD, EvenFlo, nutraceutical supplement, randomized       
controlled trial, RCT. 
INTRODUCTION  
 Sickle cell disease (SCD) is a group of red blood 
cell abnormalities that are inherited. The disease    
results from mutation in the HBB (Hemoglobin, Beta) 
which helps in making the beta-globin protein. Hetero-
zygotes produce a mixture of normal hemoglobin and 
sickle hemoglobin. Homozygotes only produce abnor-
mal beta chains that make sickle hemoglobin, and this 
results in the clinical syndrome of sickle-cell disease 
(Ralston et al., 2018). When the sickle hemoglobin is 
deoxygenated, the molecules of hemoglobin polymer-
ize to form pseudo crystalline structures known as 
‘tactoids.’ These distort the red cell membrane and 
produce characteristic sickle-shaped cells (Ralston et 
al., 2018). 
 Sickle cell disease affects millions of people 
worldwide and affects people from several races and 
groups including Hispanics, South Asians, Caucasians 
from southern Europe, and people from Middle East-
ern countries. Altogether, over 100 million people 
worldwide carry the sickle cell trait (American Society 
of Hematology [ASH], 2017; Piel, Hay, Gupta, Weath-
erall, & Williams, 2013). The disease is the most pre-
dominant monogenic disorder in humans worldwide 
and the single most common genetic disease in the 
United States, affecting approximately 100,000 Ameri-
cans (Centers for Disease Control and Prevention 
[CDC], 2019). 
 SCD occurs in approximately 300,000 births an-
nually. Nigeria, the Democratic Republic of Congo 
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and India top the list of countries with SCD births. The 
vast majority of SCD births occur in sub Saharan Afri-
ca where at least 240,000 children are born with the 
disease every year (Piel et al., 2013; Williams, 2016). 
An estimated 4,500 of these children are born in Ken-
ya (Grosse et al., 2011). Worldwide, an approximate 
50-90% of children born with SCD die undiagnosed 
before their 5th birthday (Grosse et al., 2011; Marsh, 
Kamuya, & Molyneux, 2011; World Health Organiza-
tion [WHO], 2010).  
 Once clinically diagnosed, common treatment of 
sickle cell disease involves patients initiating daily 
doses of folic acid tablets to boost their hemoglobin 
concentration levels even as there is not strong evi-
dence of this (Dixit et al., 2018).  Antibiotic prophy-
laxis (penicillin V for those not allergic) are also 
sometimes administered to prevent against pneumo-
coccal infection. Other treatments include use of Hy-
droxyurea (Borhade & Kondamudi, 2020), and blood 
and bone marrow transplant (CDC, 2020). 
 Presentation of sickle cell disease, or sickling, is 
precipitated by hypoxia, acidosis, dehydration and 
infection. Irreversibly sickled cells have a shortened 
survival (normal cells last 120 days) which may result 
in a number of acute syndromes termed ‘crises’ and 
chronic organ damage. Vaso-occlusive crises (VOCs) 
are a type of several types of crises and presents with 
severe pain with somewhat uncommon objective clini-
cal signs and are mostly identified through experience 
and subjective methods (Borhade & Kondamudi, 
2020). In the US, VOCs lead to more about 197,000 
ED visits and 356 million dollars spent on pain man-
agement every year (Lentz & Kautz, 2017). 
 Apart from the crises experienced by individuals 
with SCD, the disease has been shown to be associated 
with factors such as underweight and growth deficit, 
stunting, and wasting in children. Others include clini-
cal variables such as hemoglobin concentration,     
disease progression, nutritional factors and the type of 
treatment implemented (Kazadi, Ngiyulu, Gini-
Ehungu, Mbuyi-Muamba, & Aloni, 2017; Dos, De, 
Ivo, & Cople, 2018). Crises from SCD are generally 
managed by aggressive intravenous rehydration, oxy-
gen therapy, adequate analgesia (which often requires 
opiates) and antibiotics (Jain, Bakshi, & Krishnamurti, 
2017; Yawn & John-Sowah, 2015).  
 Despite the options available for the treatment of 
SCD, there is still a lack of reprieve from the crises 
experienced by SCD patients and the frequency of 
crises remains high among those who take the conven-
tional drugs to prevent the crises, hence, morbidity and 
mortality rates of patients remains high (Grosse, et al., 
2011; Piel et al., 2013; Pule & Wonkam, 2014; World 
Health Organization, 2010). Thus, the United Nations 
General Assembly on 22nd December, 2008, adopted 
a resolution recognizing sickle cell anemia as a public 
health problem (United Nation, 2009).  
 Given opportunities that exist to help SCD pa-
tients better manage their disease, EvenFlo nutritional 
supplement was developed as treatment and prevention 
options. The present study explored the efficacy of 
EvenFlo, a nutraceutical supplement, in conjunction 
with the traditional use of folic acid by conducting a 
clinical trial to test the effectiveness of combined use 
of these active agents.  
 
EVENFLO 
 EvenFlo is a nutritional supplement formulated to 
help manage SCD, particularly, the crises that SCD 
patients suffer and associated pain. The supplement 
was formulated to promote bone marrow cells to enter 
the cell cycle and boost the production of red blood 
cells leading to significantly increased IL-3 secretion, 
and significantly inhibited IFN-γ secretion. This leads 
to increased hemoglobin concentration, and hematocrit 
(Guo & Wang, 2006; Hsu, Ho, & Lin, 1996; Liu et al., 
2014). An earlier observation study conducted on 
EvenFlo appears to show a significant proportion of 
participants to have improved life style in the form of 
improvement of appetite, anemia, general health sta-
tus, pain management, and weight management 
(Anicet et al., 2019). 
 The active components of EvenFlo that make it 
suitable of significantly limiting SCD crises by aiding 
red blood cell production leading to increased hemo-
globin concentration and better weight management 
include atractylodes, codonopsis, corydalis, dong quai, 
jujube, licorice root or Szechuan lovage, poria, 
rehmannia root, salvia miltiorrhiza, and white peony. 
 Atractylodes are present in different forms includ-
ing atractylenolactam, biatractylolide and atractylone. 
Atractylenolactam exhibits anti-inflammatory activity 
and has anti-inflammatory, anticoagulation and gastro-
intestinal repair effects (Hoang le et al., 2016; Ji, Chen 
& Wang, 2016; Song et al., 2017; Tang, Liao, Huang, 
Lin, & Wu, 2017). Biatractylolide has a neuroprotec-
tive effect on glutamate-induced injury (Zhu et al., 
2017). Atractylone have anti-microbial and anti-
inflammatory activities (Wu et al., 2020). Codonopsis 
has active ingredients that helps in the replenishment 
of vital energy deficiency, strengthening the immune 
system, improving poor gastrointestinal function, gas-
tric ulcer and appetite and decreasing blood pressure 
(He et al., 2015). 
 Corydalis is used to treat pain, inflammation and 
gastrointestinal dysfunctions. It significantly alleviates 
the mechanical allodynia (Lee, Son & Kim, 2010). 
Dong Quai, also known as Tang Kuei or Angelica 
sinensis has blood toning and nourishing effects at-
tributed to its vitamin B12, folic acid, folinic acid, 
nicotinic acid, and biotin content (DeRosa & Cupp, 
1997). The herb contains Z-ligustilide which has a 
calming effect on the nervous system, promoting re-
laxation and reducing pain. The herb also promotes 
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hematopoiesis and can help increase blood volume 
after injury or surgery (Chao & Lin, 2011; Deng, et al., 
2009). 
 Jujube is also known as Zizyphus Lotus. It is a 
tropical and subtropical plant used in nutrition, health 
and has antimicrobial, anti-inflammatory, hypoglyce-
mic, antioxidant, and immunomodulatory effects 
(Abdoul-Azize, 2016). Licorice root (also Szechuan 
lovage or ligusticum striatum) is a flowering plant in 
the carrot family which has have therapeutic properties 
and is used to treat a painful swelling of the joints. It 
has been shown to have triterpene saponins and flavo-
noids as its main bioactive compounds. This agent 
stimulates immune responses and activates antioxidant 
enzymes (Yang, Yuan, Ma, Zhou, & Liu, 2016). 
 Poria is an extract that can help increase the index-
es of phagocyte, thymus, spleen, and promotes spleen 
antibody production, hemolytic activity, and delayed-
type hypersensitivity (Chen, Zhang, & Cheung, 2010). 
Rehmannia Root is a blood refresher and has anti-
oxidative, anti-inflammatory and anti-apoptotic effects. 
It helps to regulate deficient blood patterns such as 
anemia, irregular menses, and uterine and postpartum 
bleeding (Huang et al., 2013; Yuan, Yang, Han, & Ni, 
2018). 
 Salvia miltiorrhiza is a perennial plant with active 
ingredients that can cause coronary vasodilatation, 
suppress thromboxane formation, inhibit platelet adhe-
sion and aggregation, and scavenge free radicals.  It 
increases the activities of catalase, manganese super-
oxide dismutase, glutathione peroxidase, and coupled 
endothelial nitric oxide synthase. (Jiang et al., 2014; 
Yu et al., 2015). 
 White Peony (Paeonia sterniana) contains a 
unique glucoside called paeoniflorin, which calms 
nerves and alleviate spasm and pain (He & Dai, 2011). 
Working with other glucosides to make up total gluco-
sides of peony (TGP), it has an anti-inflammatory ef-
fect and protects against oxidative damage (Wu, Pu, 
Yu & Li, 2015). 
 
OBJECTIVES 
 The objective of this study was to investigate the 
efficacy of a combination of the EvenFlo nutritional 
supplement and the active agent, folic acid compared 




 This study was conducted at the Jaramogi Oginga 
Odinga Teaching and Referral Hospital (JOOTRH), 
Kisumu, Kenya. JOOTRH provided an ideal setting to 
conduct this study as it is a teaching hospital involved 
in medical research and houses a designated SCD Clin-
ic, the Obama Children’s Clinic, with a registered list 
of sickle cell disease patients. 
Population 
 The study population consisted of patients be-
tween ages 5 and 12 years old who were diagnosed 
with sickle cell anemia and were registered at the study 
site.  
 Before the initiation of the clinical trial, patients at 
the study site were regularly prescribed a regimen of 
daily folic acid and proguanil medications. The folic 
acid is intended to help replace depleted folate stores 
and reduce the symptoms of anemia. Folate was ex-
pected to lead to a decrease in symptoms of anemia 
and help in the prevention of hyperhomocysteinemia 
that may predispose to thrombotic events, which, in 
turn, may lead to painful episodes. Thus, folic acid was 
the main agent used among the participants for the 
management of SCD before the trial. On the other 
hand, the patients were prescribed proguanil to help 
protect them against the complications of plasmodium 
falciparum infection as a result of parasitemia. It was 
expected to prevent bone pain crises among patients in 
the event they happen to experience any crisis. 
 Since the goal of this trial was to investigate the 
effect of EvenFlo combined with folic acid versus the 
standard care (stand-alone use of folic acid), we decid-
ed not to withdraw their routine prophylaxis medica-
tion. More so, a significant proportion of the study 
population reported having two or more episodes of 
crises in the previous six months despite their regular 
care routine, hence, their qualification for participating 
in the study. The above baseline clinical and prophy-
lactic medication characteristics provided the basis for 
trial of EvenFlo without changing the status quo. 
Ethical considerations and consent 
 This study was approved by the Institutional Ethi-
cal Review Committee (ERC) at JOOTRH. The par-
ents and guardians of the participants voluntarily pre-
sented them for inclusion in this study and signed in-
formed consents. The consents included statements 
about the rights of the subjects, information to be col-
lected, confidentiality and the publication of this report 
and any other accompanying information. 
Inclusion/exclusion criteria 
 At the beginning of the study, an assessment tool 
was deployed to obtain medical history of the patients. 
The obtained history was combined with the records 
available from the hospital as well as an oral interview 
to screen the patients. Patients were included if they 
had two or more crises each month for the past 6 
months, had moderate anemia as determined by a he-
moglobin concentration between 6-8gm/dl and have a 
parent/guardian who lives with them and is responsible 
for transportation to and from the  hospital for treat-
ment. Patients were excluded if they had a history of 
transient ischemic attack or clinically overt cerebrovas-
cular accident, undergoing treatment with blood trans-
37
Muga et al.: Efficacy of the Nutritional Supplement, EvenFlo, in the Managemen
Published by Scholarly Commons @ Baptist Health South Florida, 2020
 
38     Baptist Health South Florida 
 
 
fusion therapy, receiving erythropoietin, experiencing 
VOC or any other crises of SCD or if their pre-
dominate cause of pain is not SCD related. Also ex-
cluded were those requiring treatment for more than 3 
days per week with non-steroidal anti-inflammatory 
drugs (NSAIDS), receiving chronic treatment with 
anticoagulants or antiplatelet drugs, diagnosed with 
any other concurrent disease. The subjects whose par-
ents or legal guardians declined to sign the consent 
form were also excluded.  
Sample size 
 Sample sizes were calculated using G*Power 
(Faul, Erdfelder, Buchner & Lang, 2009). Darbari et al. 
(2013) had reported that 60% of participants in a study 
reported having at least one vaso-occlusive crisis that 
required treatment within a twelve month period. With 
this in mind, a 40 or more percentage point decrease in 
vaso-occlusive crises during a study period of six 
months was of interest. Thus, assuming proportion of 
participants reporting crises in the control group and 
the intervention group of 60% and 20% respectively, 
with a two-sided significance of 0.05 and an 80% pow-
er, a minimum of 20 subjects was required per group 
for a total of 40 subjects for the study. 
 On the other hand, to estimate an appropriate sam-
ple size for hemoglobin concentration and weight, a 
clinically significant medium effect, defined by Cohen 
(1988) to be Cohen’s f of 0.25 (equivalent to 0.06 par-
tial η2) was of interest. With two groups, measure-
ments at 3 different points in time, 0.05 significance 
level, rho (ρ) of 0.25 (a conservative approach), a con-
servative conventional non-sphericity correction epsi-
lon (ε) of 0.75 and a 80% power, a minimum of 25 
subjects was required per group for a total of 50 sub-
jects for the study. Given these estimated minimum 
sample sizes and the need to have a buffer in case of 
attrition, 70 subjects were enrolled into the study. 
Procedure and subject allocation 
 At the point of screening, informed consents were 
obtained and the SCD statuses of the patients were 
confirmed by clinicians using a multi-parameter elec-
trophoresis machine. After each confirmation, the cli-
nicians obtained the subject’s demographic infor-
mation and scheduled their first visit.  
 This was a double-blind study, thus, none of the 
researchers, clinicians or the guardians knew the par-
ticipants enrolled in either group or were taking the 
intervention capsules. Only the pharmacist who dis-
pensed the capsules via randomization numbers was 
had knowledge of subjects’ group status. Subjects were 
randomized in a 1:1 ratio using stratified block ran-
domization particularly given that this was not a large 
clinical trial. 
 At the first visit, examinations were conducted and 
clinical information obtained. Hemoglobin concentra-
tions were measured using a Hemoglobin testing sys-
tem. Upon all examinations and laboratory test results 
showing no present crises or diseases, each participant 
received an envelope containing the medication to be 
used for the next 30 days. The subjects in the interven-
tion group received 30 capsules of Folic Acid 500 mi-
crogram (mcg) and 60 capsules of EvenFlo 500 milli-
gram (mg). The Folic Acid was to be used once a day 
and the EvenFlo twice daily. Subjects in the control 
group received 30 capsules of Folic Acid (500 mg) to 
be used once a day.  
Participant follow-up 
 Subjects were followed for six months with one 
visit per month. At the conclusion of the first visit, 
each subject was scheduled for a first follow-up visit, 
to occur 4 weeks following the initial visit. During 
each visit, subjects received additional supply of medi-
cation. The data from the initial visits were considered 
baseline. 
 When the subjects returned for each follow-up 
visit, their clinical information were obtained and any 
medical events since the previous visit were document-
ed. Any crises or medical events that happened in-
between the visits were documented by the parents and 
guardians and reported at the next visit. 
Measurement 
 The primary outcome variable was vaso-occlusive 
crisis (VOC) as characterized by excruciating pain. 
These mostly include acute chest, abdominal, back and 
joint pains. Reported cases of yellow eyes in either 
group were not considered VOCs and were not includ-
ed in our analysis. Hemoglobin concentration and 
weight index data were considered secondary out-
comes. These variables are adequate to assess effects 
of SCD given their association with the disease (Dos, 
De, Ivo, & Cople, 2018; Kazadi, Ngiyulu, Gini-
Ehungu, Mbuyi-Muamba, & Aloni, 2017). These vari-
ables were measured during each visit. 
Quality assurance 
 At the end of each week during the study period, a 
quality assurance meeting was held with clinicians, the 
first author and consulting pediatrician in order to  re-
view the activities and information collected that week. 
This included the review of completed clinical research 
forms, the clinicians’ examinations, decisions and the 
laboratory results. Clinicians gave instructions on 
swallowing of capsules and the first dose was taken at 
the hospital, in the presence of an adult guardian/
parent, who was chosen as a “medication buddy” to 
give the capsule at the right time and as per the instruc-
tions.  
Statistical analysis 
 Demographic characteristics, rates of VOC experi-
enced, hemoglobin concentration levels and weight 
indices were compared between the participants in the 
intervention and control groups. The rates of vaso-
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occlusive crises experienced by the two groups were 
compared using the two proportion Z-test. We used a 
two-way mixed-design Analysis of Variance 
(ANOVA) model to compare mean hemoglobin con-
centration levels and mean weights at three different 
time points (baseline, after 3 months and after 6 
months), from the two study groups. Time was the 
within-subject factor and group was the between-
subject factor. The assumptions of the model were 
examined. Statistical significance was set at p < 0.05 
except for Box’s M Tests for which we used p < .001 
given that Hahs-Vaughn (2016) and Tabachnick & 
Fidell (2001) recommended ignoring the test or using 
smaller alpha level with unequal groups due to the 
test’s sensitivity. Confidence intervals (CIs) were esti-
mated with 95% certainty. Data transformation was 
considered in rectifying the violation of the normality 
assumption, however, the results did not significantly 
differ from those of the untransformed data; thus, the 
untransformed results were retained for reasons of sim-
plicity and the robustness of the ANOVA test. Statisti-
cal analyses were performed using SPSS 24 by IBM. 
Graphs were produced using RStudio 1.1.463 (RStudio 
Team, 2015).  
 
RESULTS 
 A total of 120 SCD children were screened of 
which 70 children meeting the age requirement of 5 to 
12 years were enrolled into the study. Thirty five sub-
jects were allocated into the treatment (envelope + 
standard of care) group and 35 into the control 
(standard of care) group. Thirty-two (91.4%) subjects 
in the treatment group and 29 (85.7%) in the control 
completed 6 months study follow-up and had complete 
data for analysis (Figure 1). All subjects were of Afri-
can race. The baseline characteristics were similar  
between the two groups in terms of age, gender, 
weight, and hemoglobin level (Table 1). 
 The primary outcomes data being the amount of 
VOCs experienced by the subjects were compared 
between the two groups. With all 27 (93.1%) of the 29 
subjects in the control group experiencing at least one 
form of crises by the end of the 6 months trial com-
pared to none (0.0%) of the 32 subjects in the treat-
ment group, there was a significant difference in the 
proportion of subjects that experienced at least one 
VOC (proportion difference = 0.931, 95% CI = 0.93 to 
1.00, Z = 7.05, p <  .001). This represents a 93.1% dif-
ference in the proportions of subjects that experienced 
VOCs. Further analysis of the crises experienced by 
the subjects in the control group during the trial shows 
that 2 (6.9%) experienced no crises, 10 (34.5%) expe-
rienced one crisis, 14 (48.3%) experienced two crises 
and 3 (10.3%) experienced three crises (Table 2).  
 For the secondary outcome variable of hemoglo-
bin concentration, there were no outliers, as assessed 
through studentized residuals. The assumption of nor-
mality was assessed using the Kolmogorov-Smirnov 
test. The assumption was partially violated with only 
four of the six subgroups of data satisfying the as-
sumption (p > .05), the remaining two subgroups oth-
erwise. There was homogeneity of variances, as as-
sessed by Levene's test of homogeneity of variances 
(p > .05) and homogeneity of covariances as assessed 
by Box's M test (p > .001). In testing if the variances 
of the differences between the related groups of the 
within-subject factor for all groups of the between-
subjects factor are equal, Mauchly's test of sphericity 
indicated that the assumption of sphericity was met for 
the two-way interaction, χ2(2) = 4.92, p = .086. For the 
test of interaction effect, the results showed that there 
was a statistically significant interaction between the 
treatment and time, on hemoglobin level, F(2, 118) = 
4.08, p = .019, partial η2 = .065. Due to the statistical-
ly significant interaction between the treatment and 
time, we determined the simple main effects of group. 
Data are mean ± standard error. The results showed 
that hemoglobin concentration was statistically signifi-
cantly higher in the intervention group at the end of the 
trial (10.67 ± 0.26 g/dL) compared to the control group 
(9.22 ± 0.27 g/dL), F(1, 59) = 15.17, p < .001, partial 
η2 = .205 (Figure 2). The intervention group improved 
their mean hemoglobin concentration from baseline by 
2.92 g/dL, 95% CI [2.33, 3.51] compared to 1.77 g/dL, 
95% CI [1.00, 2.54]. Mean hemoglobin concentrations 
at the three periods considered are shown in table 3. 
 Also for weight, another secondary outcome varia-
ble, there were no outliers as assessed through the  
residuals. The assumption of normality was also     










Age (Years)       
      Mean ± SD 8.5 ± 1.8 8.3 ± 2.1 8.4 ± 1.9 
      Min 6.0 5.0 5.0 
      Max 11.0 11.0 11.0 
Gender       
      Female n (%) 17 (53.1) 15 (51.7) 32 (52.5) 
Race       
     Black/African n (%) 32 (100) 29 (100) 61 (100) 
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Table 2: Vaso-Occlusive Crises Experienced During Clinical Trial 
 




Table 3: Estimated Marginal Means for Weight and Hemoglobin 
 
*Data represent Mean ± SE. 
 
Figure 1. CONSORT diagram for study enrollment  
 
 
Number of Crises Intervention Group Control Group 
None 32 (100.0) 29  (6.9) 
One 0 (0.0) 10 (34.5) 
Two 0 (0.0) 14 (48.3) 
Three 0 (0.0) 3 (10.3) 




Intervention Group 7.8 ± 0.3 22.2 ± 0.9 
Control Group 7.5 ± 0.3 22.8 ± 0.9 
    
3 Months 
Intervention Group 8.0 ± 0.3 24.8 ± 0.9 
Control Group 7.5 ± 0.3 21.9 ± 0.9 
    
6 Months 
Intervention Group 10.7 ± 0.3 26.6 ± 1.0 
Control Group 9.2 ± 0.3 21.8 ± 0.8 
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partially violated with only the three subgroups of data 
from the intervention group satisfying the assumption 
(p >  .05) while the three subgroups from the control 
violated it. There was homogeneity of variances 
(p > .05) and covariances (p > .001), as assessed by 
Levene's test of homogeneity of variances and Box's M 
test, respectively. Mauchly's test of sphericity showed 
that the assumption of sphericity was not met for the 
two-way interaction, χ2(2) = 6.17, p = .046. With this 
violation and the estimated value of epsilon greater 
than 0.75, we adopted the Huynh-Feldt correction 
based on the recommendations of Vieira (2017) and 
Girden (1992). The results of the interaction test 
showed that there was a statistically significant interac-
tion between the treatment and time, on weight, F
(1.90, 112.28) = 174.98, p < .001, partial η2 = .748, ε 
= .952, thus, simple main effects were determined. 
Data are mean ± standard error. The results showed 
that after 3 months, the intervention group had a mean 
weight (24.79 ± 0.87 Kg) statistically significantly 
higher than the control group (21.92 ± 0.91 Kg), F(1, 
59) = 5.17, p = .027, partial η2 = .081 (Figure 3). At 
the end of the 6 months trial, the intervention group 
had a mean weight of 26.63 ± 0.89 Kg, which was 
significantly higher than 21.79 ± 0.93Kg of the control 
group, F(1, 59) = 14.19, p < .001, partial η2 = .194. 
Within the six months of trial, the intervention group 
increased their mean weight from the baseline by a 
mean of 4.47 Kg, 95% CI [4.02, 4.92] while the con-
trol group experienced a decrease (-1.05 Kg, 95%      
CI [-1.60, -0.51] in their mean weight in the same time 
period. Mean weight at the three time periods consid-
ered are shown in table 3. 
 
DISCUSSION 
 EvenFlo is an effective agent in reducing the fre-
quency of sickle cell disease crises as evidenced by a 
percentage difference of over 93.1% in the amount of 
individuals that experience any form of crises during 
the trial. While no subject experienced an episode of 
VOC among the treatment group for the 6 months, 
93.1% of the subjects in the control group experienced 
at least one crises.  
 Evenflo is also effective in increasing the hemo-
globin concentration of the blood for SCD patients. At 
the end of the 6 months trial period, the subjects in the 
intervention group had increased their hemoglobin 
concentration by a mean of 2.92 g/dl; this is signifi-
cantly higher than 1.77 g/dl observed among those that 
took only folic acid. Similarly, the nutritional supple-
ment saw the subjects in the intervention group      
increase their mean weight from the baseline by a 
mean of 4.47 Kg, while the control group experienced 
a decrease of 1.05 Kg in their mean weight during the 
trial period.  
 Overall, EvenFlo helps in the management of 
SCD by preventing VOCs due to SCD, increasing  
hemoglobin concentration and increasing weight; this 
is consistent with the findings of Anicet et al. (2019).  
 We imagine that EvenFlo provides a better alter-
native for SCD patients than some of the options previ-
ously available. For instance, hydroxyurea is common-
ly used to manage SCD. With the benefits derived 
from hydroxyurea also come the side effects of neutro-
penia, bone marrow suppression and mild peripheral 
blood cytopaenia, elevation of hepatic enzymes, ano-
rexia, nausea, vomiting and infertility (Agrawal, Patel, 
Figure 2.  
Profile plot of hemoglobin concentration. 
Figure 3. 
Profile plot of weight. 
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Shah, Nainiwal, & Trivedi, 2013). These side effects 
are conspicuously absent with EvenFlo. 
Side effects 
 A single participant in the treatment group had 
mild diarrhoea after initiation of treatment; the diar-
rhoea stopped after a couple of days and the participant 
continued with the treatment until the end of the study. 
The diarrhoea may have been a side effect of the nutri-
tional supplement, however, the single occurrence was 
not sufficient to draw definitive conclusions. No other 
possible side effect was reported. 
Limitations 
 A limitation of the study relates to our passive 
follow-up of subjects. Limitations of this approach is a 
reliance on the subjects and their parents/guardians to 
narrate any crises experienced between any two visits 
at the next visit, there is a possibility of not been able 
to capturing certain crises. A system for real-time re-
porting can be implemented in the future studies.  
 Another limitation has to do with a subjective 
method of measuring compliance. We relied on the 
parents/guardians to see to the proper use of the sup-
plements and oral report of compliance. Some parents/
guardians reported that their wards had difficulty in 
swallowing the capsules and we were not able to do 
directly the administration of the supplements but re-
lied on parents/guardians to administer it daily). A 
tracking system can be provided to monitor compli-
ance. 
 Additionally, the six month study period is some-
what short, a longer study period of 12 months or more 
can be considered in the future. Also, the impact of 
EvenFlo alone on SCD patients without the administra-
tion of folic acid may be explored in the future while 
addressing the limitations mentioned.  
 Furthermore, none of female subjects in this study 
was known to have started their monthly period yet. 
Given that SCD is associated with delay in menarche 
and gonadal dysfunction (Kopeika et al., 2019; Stimp-
son, Rebele, & Debaun, 2015), a study on young wom-
en and women of reproductive age may help under-
stand the effect of this supplement on that group. 
 
CONCLUSION 
 The results from this randomized controlled trial 
showed that EvenFlo in addition to folic acid, is an 
effective agent in the management of SCD. Thus, we 
recommend the use of EvenFlo for the management of 
SCD patients as its effect would be useful in signifi-
cantly limiting the onset of crises suffered by these 
individuals as well as boosting their hemoglobin con-
centration and weight indices possibly leading to im-
proved quality of lives. 
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